查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1982764

全球腦膜炎雙球菌疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Meningococcal Vaccine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計腦膜炎雙球菌疫苗市場將從 2025 年的 29.6 億美元成長到 2034 年的 51.6 億美元，2026 年至 2034 年的複合年成長率為 6.39%。

由於人們加強了預防腦膜炎雙球菌感染疾病，全球腦膜炎雙球菌疫苗市場經歷了顯著成長。腦膜炎球菌感染是嚴重的細菌感染，可引起病菌感染和血液感染疾病。免疫接種計畫在降低疾病的發生率方面發揮了至關重要的作用，尤其是在嬰幼兒、青少年和高風險族群中。

腦膜炎球菌疫苗市場的主要促進因素包括公共衛生工作的加強和免疫接種計劃的擴大。世界各國政府和醫療機構都在積極進行疫苗宣傳活動，旨在預防疫情爆發並保護弱勢族群。此外，疫苗研發的進步也推動了更有效、保護更廣泛的疫苗的研發。

隨著全球醫療衛生體系加強疾病預防策略，腦膜炎雙球菌疫苗市場預計將會擴大。疫苗技術的持續研究以及人們對疫苗接種益處的認知不斷提高，有望促進疫苗接種率的提升。此外，發展中地區醫療衛生基礎設施的不斷完善，預計也將改善腦膜炎雙球菌疫苗的可近性。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球腦膜炎雙球菌疫苗市場：按類型分類

  • 市場分析、洞察與預測
  • 二價
  • 四價
  • 其他

第5章 全球腦膜炎雙球菌疫苗市場：依品牌分類

  • 市場分析、洞察與預測
  • 梅納克特拉
  • Membeo
  • 尼門里克斯
  • 托爾門巴
  • 維克塞洛
  • 其他

第6章 全球腦膜炎雙球菌疫苗市場：依年齡層別分類

  • 市場分析、洞察與預測
  • 嬰幼兒（0-2歲）
  • 兒童及成人（2歲以上）

第7章 全球腦膜炎雙球菌疫苗市場：依血清型分類

  • 市場分析、洞察與預測
  • A型血清型
  • B型血清型
  • C型血清型
  • 血清型 W-135
  • Y型血清型

第8章 全球腦膜炎雙球菌疫苗市場：依銷售管道分類

  • 市場分析、洞察與預測
  • 私人的
  • 一般的

第9章 全球腦膜炎雙球菌疫苗市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第10章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第11章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Pfizer Inc
    • Sanofi
    • Serum Institute Of India Ltd
    • GSK Plc
    • Merck & Co. Inc
    • Walvax Biotechnology Co. Ltd
    • Chongqing Zhifei Biological Products Co. Ltd
    • Baxter International
    • CSL Limited
    • Bavarian Nordic Incepta Vaccine Ltd
    • Sinovac Biotech Ltd
    • Novartis
    • Panacea Biotec Ltd
簡介目錄
Product Code: VMR11212373

The Meningococcal Vaccine Market size is expected to reach USD 5.16 Billion in 2034 from USD 2.96 Billion (2025) growing at a CAGR of 6.39% during 2026-2034.

The global meningococcal vaccine market has experienced significant growth due to increasing efforts to prevent meningococcal disease, a serious bacterial infection that can cause meningitis and bloodstream infections. Vaccination programs have played a crucial role in reducing the incidence of this disease, particularly among infants, adolescents, and individuals at higher risk.

Key drivers of the meningococcal vaccine market include growing public health initiatives and expanding immunization programs. Governments and healthcare organizations are promoting vaccination campaigns to prevent outbreaks and protect vulnerable populations. Additionally, advancements in vaccine research have led to the development of more effective and broader protection vaccines.

In the future, the meningococcal vaccine market is expected to expand as global healthcare systems strengthen disease prevention strategies. Continued research in vaccine technology and increasing awareness about immunization benefits may support higher vaccination coverage. Furthermore, expanding healthcare infrastructure in developing regions will likely increase access to meningococcal vaccines.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

  • Bivalent
  • Quadrivalent
  • Others

By Brand

  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero
  • Others

By Age Group

  • Infants (0 to 2 years)
  • Children And Adults (2 years & above)

By Serotype

  • Serotype A
  • Serotype B
  • Serotype C
  • Serotype W-135
  • Serotype Y

By Sales Channel

  • Private
  • Public

COMPANIES PROFILED

  • Pfizer Inc, Sanofi, Serum Institute of India Ltd, GSK plc, Merck Co Inc, Walvax Biotechnology Co Ltd, Chongqing Zhifei Biological Products Co Ltd, Baxter International, CSL Limited, Bavarian Nordic Incepta Vaccine Ltd, Sinovac Biotech Ltd, Novartis, Panacea Biotec Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. Bivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Quadrivalent Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY BRAND 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Brand
  • 5.2. Menactra Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Menveo Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Nimenrix Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Trumenba Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Bexsero Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY AGE GROUP 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Age Group
  • 6.2. Infants (0 to 2 years) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Children And Adults (2 years & above) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY SEROTYPE 2022-2034 (USD MN and Million Doses)

  • 7.1. Market Analysis, Insights and Forecast Serotype
  • 7.2. Serotype A Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.3. Serotype B Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.4. Serotype C Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.5. Serotype W-135 Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 7.6. Serotype Y Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY SALES CHANNEL 2022-2034 (USD MN and Million Doses)

  • 8.1. Market Analysis, Insights and Forecast Sales Channel
  • 8.2. Private Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 8.3. Public Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 9. GLOBAL MENINGOCOCCAL VACCINE MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.2.1 By Type
    • 9.2.2 By Brand
    • 9.2.3 By Age Group
    • 9.2.4 By Serotype
    • 9.2.5 By Sales Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.3.1 By Type
    • 9.3.2 By Brand
    • 9.3.3 By Age Group
    • 9.3.4 By Serotype
    • 9.3.5 By Sales Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.4.1 By Type
    • 9.4.2 By Brand
    • 9.4.3 By Age Group
    • 9.4.4 By Serotype
    • 9.4.5 By Sales Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.5.1 By Type
    • 9.5.2 By Brand
    • 9.5.3 By Age Group
    • 9.5.4 By Serotype
    • 9.5.5 By Sales Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 South East Asia
    • 9.5.11 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 9.6.1 By Type
    • 9.6.2 By Brand
    • 9.6.3 By Age Group
    • 9.6.4 By Serotype
    • 9.6.5 By Sales Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL MENINGOCOCCAL VACCINE INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 Pfizer Inc
    • 11.2.2 Sanofi
    • 11.2.3 Serum Institute Of India Ltd
    • 11.2.4 GSK Plc
    • 11.2.5 Merck & Co. Inc
    • 11.2.6 Walvax Biotechnology Co. Ltd
    • 11.2.7 Chongqing Zhifei Biological Products Co. Ltd
    • 11.2.8 Baxter International
    • 11.2.9 CSL Limited
    • 11.2.10 Bavarian Nordic Incepta Vaccine Ltd
    • 11.2.11 Sinovac Biotech Ltd
    • 11.2.12 Novartis
    • 11.2.13 Panacea Biotec Ltd